Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCommunity-Care Lumizyme Coverage Prior Auth | Open…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Lumizyme (alglucosidase alfa) — Medical Benefit Medication Utilization Policy

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical benefit coverage criteria, authorization, quantity limits, and coding for Lumizyme (alglucosidase alfa) for treatment of Pompe disease for Community-Care members.

    Policy Summary
    PayerCommunity-Care
    PolicyLumizyme (alglucosidase alfa) — Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2024
    Last ReviewApr 1, 2024
    Next Review DateN/A
    Key ActionObtain prior authorization and provide diagnostic confirmation, prescriber specialty, and member weight for approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20 mg/kg q2wAuthorized dosing per policy
    1 yearAuthorization period length
    J0221HCPCS code for Lumizyme 10 mg
    Specialist required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Prescriber requirement
    Weight requiredWeight required

    Coverage Criteria for Lumizyme (alglucosidase alfa)

    Initial Therapy — Infantile-onset Pompe disease

    Covered when ALL of the following are met for infantile-onset Pompe disease:

    Infantile-onset criteria: (1) Clinical diagnosis of infantile-onset Pompe disease confirmed by genetic sequencing OR acid alpha-glucosidase enzyme assay; (2) Prescribed by a medical geneticist or neuromuscular specialist

    Initial Therapy — Late-onset Pompe disease

    Covered when ALL of the following are met for late-onset Pompe disease:

    Late-onset criteria: (1) Clinical diagnosis of late-onset Pompe disease confirmed by genetic sequencing OR acid alpha-glycosidase enzyme assay; (2) Prescribed by a medical geneticist or neuromuscular specialist; (3) Patient is experiencing symptoms or objective signs of Pompe disease

    Continuation Therapy

    Covered when ALL of the following are met for continuation:

    Continuation criteria: (1) Diagnosis of Pompe disease; (2) Member is benefitting from therapy, is being monitored, and is appropriate to continue therapy

    For initial approval in infantile-onset Pompe disease, coverage requires a confirmed clinical diagnosis by either genetic sequencing or an acid alpha-glucosidase enzyme assay. Additionally, the prescription must come from a medical geneticist or neuromuscular specialist. These requirements ensure diagnostic certainty and specialist oversight prior to authorizing enzyme replacement therapy with alglucosidase alfa.

    For late-onset Pompe disease, initial coverage similarly requires diagnostic confirmation by genetic sequencing or an acid alpha-glucosidase enzyme assay, and the drug must be prescribed by a medical geneticist or neuromuscular specialist. In addition, the patient must be symptomatic or have objective signs of Pompe disease to meet initial approval criteria.

    Initial Therapy

    Initial therapy

    Covered when ALL of the following are met:

    Infantile initial: Clinical diagnosis confirmed by genetic sequencing OR acid alpha-glucosidase enzyme assay; prescribed by a medical geneticist or neuromuscular specialist
    Late-onset initial: Clinical diagnosis confirmed by genetic sequencing OR acid alpha-glycosidase enzyme assay; prescribed by a medical geneticist or neuromuscular specialist; patient is symptomatic or has objective signs

    Continuation Therapy

    Continuation therapy

    Covered when ALL of the following are met:

    Continuation: Diagnosis of Pompe disease and member is benefitting from therapy, is being monitored, and is appropriate to continue therapy

    Coding and Dosing

    Applicable HCPCS CodesHCPCS
    J0221Injection, alglucosidase alfa, (Lumizyme), 10 mg
    inv-07: Dose interval
    Dose interval20 mg/kg every 2 weeks
    Authorization period1 year (if approved)
    HCPCS code (unit)J0221 — Injection, alglucosidase alfa (Lumizyme), 10 mg

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for alglucosidase alfa (Lumizyme). When criteria are met, authorization will specify dosing of 20 mg/kg every 2 weeks. A current patient weight must be provided with the request. Authorizations, if approved, will be issued for up to one year.

    • Required dosing when approved: 20 mg/kg every 2 weeks
    • Weight required for approval: provide current patient weight with request
    • Authorization period: up to 1 year (subject to benefit changes)
    Note

    Provider Action — Submit Complete Request

    Submit prior authorization requests and supporting documentation to Community-Care per payer procedures. Ensure the prescriber specialty and required documentation (see documentation callout) are included to avoid processing delays.

    • Include prescriber specialty on the request (medical geneticist or neuromuscular specialist preferred)

    Site of Care

    Note

    Site of care

    No site-of-care restrictions or special setting requirements are specified in the policy.

    Quantity Limits and Dosing Calculations

    inv-17: alglucosidase alfa (Lumizyme)
    Dosing (quantity limit basis)20 mg/kg every 2 weeks
    Weight requirementMember weight is required for approval and quantity calculation
    Authorization period noteIf approved, coverage is allowed for one year

    Definitions

    inv-13: Infantile-onset Pompe disease
    DefinitionInfantile-onset Pompe disease: clinical diagnosis of infantile-onset Pompe disease
    Diagnostic confirmationConfirmed by genetic sequencing OR acid alpha-glucosidase enzyme assay
    Prescriber requirementMust be prescribed by a medical geneticist or neuromuscular specialist
    inv-14: Late-onset Pompe disease
    DefinitionLate-onset Pompe disease: clinical diagnosis of late-onset Pompe disease
    Diagnostic confirmationConfirmed by genetic sequencing OR acid alpha-glycosidase enzyme assay
    Clinical requirement

    Background

    Pompe disease is an inherited deficiency of acid alpha-glucosidase that presents as either infantile-onset or late-onset disease. Treatment is with enzyme replacement therapy using alglucosidase alfa (Lumizyme). Per policy, diagnostic confirmation by genetic sequencing or an acid alpha-glucosidase enzyme assay is required for initiation, and prescribers must be a medical geneticist or neuromuscular specialist. When approved, dosing is authorized at 20 mg/kg every 2 weeks and a member weight must be provided to calculate quantities; approvals are issued for one year when criteria are met.

    Policy Summary
    PayerCommunity-Care
    PolicyLumizyme (alglucosidase alfa) — Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2024
    Last ReviewApr 1, 2024
    Next Review DateN/A
    Key ActionObtain prior authorization and provide diagnostic confirmation, prescriber specialty, and member weight for approval.
    SourceLink
    On This Page
    Coverage Criteria for Lumizyme (alglucosidase alfa)Initial TherapyContinuation TherapyCoding and DosingProvider Actions and RequirementsSite of CareQuantity Limits and Dosing CalculationsDefinitionsBackground
  1. Provide member weight and proposed dosing schedule
  2. Attach clinical documentation confirming diagnosis and baseline/ongoing monitoring
  3. Documentation Required

    Required Documentation

    Required documentation must be submitted with the prior authorization request to establish medical necessity and support approval.

    • Diagnostic confirmation of Pompe disease via genetic sequencing or acid alpha-glucosidase enzyme assay
    • Prescriber specialty: medical geneticist or neuromuscular specialist (document specialty)
    • For late-onset disease: documentation of symptoms or objective signs of Pompe disease
    • Evidence of clinical benefit for continuation requests and documentation of ongoing monitoring
    • Current member weight (for dosing/quantity calculation)
    Denial Risk

    Triggers for Possible Denial

    Requests may be denied or delayed if required information is missing or criteria are not met. Review these common triggers to reduce risk of denial.

    • Missing diagnostic confirmation (no genetic testing or enzyme assay provided)
    • Prescriber specialty not documented or prescriber outside recommended specialties
    • No current patient weight provided
    • For late-onset Pompe disease: absence of documented symptoms or objective signs when required
    • Lack of documentation demonstrating benefit for continuation requests
    Patient must be experiencing symptoms or objective signs of Pompe disease
    Prescriber requirementMust be prescribed by a medical geneticist or neuromuscular specialist